Table 11.
Studies on the use of BoNT-A in psoriasis. RCT, randomized clinical trial; VAS, Visual Analogue Scale; TCS Total Clinical Score.
| First Author [Ref.], year | Type of Study | n (Type of Psoriasis) | BoNT-A Doses | Retreatment | Follow-Up | Results |
|---|---|---|---|---|---|---|
| Zanchi [178], 2008 | Observational, no RCT | 15 (inverse psoriasis) | 50-100 U | Not reported | 12 weeks | Improvement in VAS scale score; photographic assessment with improvement of erythema, infiltration (87%) |
| Saber [181], 2011 | Case report | 1 (inverse psoriasis and hyperhidrosis) | 100 U per axilla | No | 4 weeks | Greatly improved (photographic documentation) |
| Gilbert [182], 2014 | Case report | 1 (plaque psoriasis) | 30 U for a single plaque | No | 8 months | Complete remission but recurrence after 8 months. |
| Todberg [186], 2018 | Exploratory, multicenter, randomized double-blinded trial (BoNT-A vs. vehicle). | 8 (plaque psoriasis) | 36 U for a single plaque | No | 8 weeks | No clinical or histological differences from the vehicle |
| Aschenbeck [179], 2018 | Open-label pilot study | 8 (plaque psoriasis) | Variable number of units per plaque (average units, 53; range, 25–92) | No | 10 weeks | PASI and BSA reduction |
| González [185], 2018 | Descriptive cross-sectional study | 8 (plaque psoriasis) | Variable number of units per plaque (maximum 50 U) | No | 4 weeks | All parameters evaluated (desquamation, erythema and infiltration) for TCS score showed improvement |